Crucell ADR CRXL
-
DSM's Strong Nutrition Segment Offset its Volatile Chemical and Polymer Segment
… food and feed ingredients products. The Martek acquisition, the JV with POET Group for cellulosic ethanol, and the JV with Crucell for bio products all represent this trend. We think these ongoing investments should bolster DSM's nutritional segment …
-
This Biopharmaceutical Could Be Something Special
By Steven Bulwa : Not all companies are created equal. In technology it is usually something proprietary that sets you apart. This is why I am drawn to technology stocks, because that's where you can find the businesses that are hard to duplicate or commoditize because of the uniqueness and ...
-
Global Economy: Watch the Clouds Beyond the Silver Lining
Given the advancement of several licensee-developed products into clinical trials, we are placing our fair value estimate for Crucell CRXL under review as we incorporate the value of the firm's technologies and several potential future products and royalties into our valuation.
-
Taking Advantage Of Johnson & Johnson's Unstickiness
… REMICADE and SIMPONI as well as the company's acquisition of Crucell . The spat between Merck and Johnson & Johnson was a result ..... Johnson had a co-marketing agreement. With its acquisition of Crucell , Johnson & Johnson gains a strong Complete Story »
-
What's Different This Time: Mergers And Takeovers
By Global Investing Editor : The most dangerous four words in English, we're told, are “it's different this time.” Having run a global investing newsletter for 22 years, I can spot what's unusual compared to past decades. The new trend in 2011 is clear. This year is not a repeat of 2008, despite ...
-
TAKE-A-LOOK- Crucell to be delisted after J&J buyout
AMSTERDAM, April 11 (Reuters) - Dutch biotech firm Crucell will be delisted from Euronext Amsterdam after the close of trading on Monday, following its takeover by U.S. healthcare company Johnson...
-
Our Top Five Biotech Acquisition Candidates… interest in companies that have very robust pipelines in very popular areas. So for example, OSI and Abraxis in cancer, Crucell and Zymogenetics in infectious disease. And then also in MS, we saw Facet acquired by Abbott as well as Sanofi's acquisition …
in very popular areas. So for example, OSI and Abraxis in cancer, Crucell and Zymogenetics in infectious disease. And then also in MS, we saw Facet acquired by Abbott as well as Sanofi's acquisition of -
Crucell's Impending Acquisition Insulates Firm's Valuation from 4Q Supply Issues
… issues continued to weigh on the Crucell 's CRXL financial performance in the fourth ..... production facility last year. Crucell resumed shipments of the non ..... development expenses to support Crucell 's growing pipeline, caused the …
-
UPDATE 1- Crucell wins approval to keep selling Quinvaxem
* WHO says will accept sales of Crucell 's childhood vaccines
-
Crucell investor Van Herk to tender shares to J&J offer
AMSTERDAM (Reuters) - Crucell NV shareholder Van Herk said on Wednesday it would tender its shares to U.S. healthcare company Johnson & Johnson's agreed 1.75 billion euro ($2.4 billion) offer...